AB 171

Drug Profile

AB 171

Alternative Names: AB171; LA 419

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lacer
  • Developer ARCA biopharma Inc; Lacer
  • Class Furans; Heart failure therapies; Organic nitrates; Small molecules; Sugar alcohols; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chronic heart failure; Peripheral arterial disorders
  • No development reported Ischaemic heart disorders

Most Recent Events

  • 16 Nov 2017 ARCA biopharma receives patent covering AB 171 in Europe, including Denmark, France, Germany, Ireland, Italy, the Netherlands, Spain, Sweden, Switzerland and the United Kingdom
  • 16 Nov 2017 ARCA biopharma has patents pending for AB 171 in USA and Canada
  • 16 Nov 2017 No development reported - Phase-II for Ischaemic heart disorders in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top